Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Organon, Roivant
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
Shares of Roivant, which owns 86% of
Dermavant
as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However,
Organon
was down 1.4%.
Dermavant
's Vtama cream, approved by ...
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.
FiercePharma
8d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon
is set to acquire Roivant’s immuno-dermatology subsidiary
Dermavant
for up to $1.2 billion, the companies ...
pharmaphorum
7d
Organon makes dermatology play with $1.2bn Dermavant buyout
Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...
NJBIZ
7d
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
8d
on MSN
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
7d
Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...
The Pharma Letter
8d
Organon to acquire Dermavant in back-loaded deal
Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.
Pharmabiz
6d
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
8d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
7d
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
4d
Organon: A Surprising Deal
Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback